Use of FOXP2 as a marker for abnormal lymphocytes and as a target for therapy of disorders associated with abnormal lymphocytes

Details for Australian Patent Application No. 2009329380 (hide)

Owner Isis Innovation Limited

Inventors Banham, Alison; Campbell, Andrew; Gascoyne, Duncan; Lyne, Linden

Agent Davies Collison Cave

Pub. Number AU-A-2009329380

PCT Pub. Number WO2010/070278

Priority 0823020.3 17.12.08 GB

Filing date 16 December 2009

Wipo publication date 24 June 2010

International Classifications

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

7 July 2011 PCT application entered the National Phase

  PCT publication WO2010/070278 Priority application(s): WO2010/070278

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009329384-Cement compositions comprising stevia retarders

2009329370-Clip and method for the mounting of panels